ALCON INC (2U3.DE) Stock Price & Overview

FRA:2U3CH0432492467

Current stock price

62.6 EUR
-0.14 (-0.22%)
Last:

The current stock price of 2U3.DE is 62.6 EUR. Today 2U3.DE is down by -0.22%. In the past month the price decreased by -2.43%.

2U3.DE Key Statistics

52-Week Range61.98 - 85.94
Current 2U3.DE stock price positioned within its 52-week range.
1-Month Range61.98 - 69.56
Current 2U3.DE stock price positioned within its 1-month range.
Market Cap
31.281B
P/E
23.98
Fwd P/E
21.47
EPS (TTM)
2.61
Dividend Yield
0.48%

2U3.DE Stock Performance

Today
-0.22%
1 Week
-4.05%
1 Month
-2.43%
3 Months
-8.24%
Longer-term
6 Months -4.16%
1 Year N/A
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

2U3.DE Stock Chart

ALCON INC / 2U3 Daily stock chart

2U3.DE Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to 2U3.DE.


Chartmill TA Rating
Chartmill Setup Rating

2U3.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to 2U3.DE. 2U3.DE has an excellent financial health rating, but there are some minor concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

2U3.DE Earnings

On February 24, 2026 2U3.DE reported an EPS of 0.78 and a revenue of 2.70B. The company missed EPS expectations (-1.57% surprise) and missed revenue expectations (-1.53% surprise).

Next Earnings DateMay 5, 2026
Last Earnings DateFeb 24, 2026
PeriodQ4 / 2025
EPS Reported$0.78
Revenue Reported2.702B
EPS Surprise -1.57%
Revenue Surprise -1.53%

2U3.DE Forecast & Estimates

20 analysts have analysed 2U3.DE and the average price target is 91.81 EUR. This implies a price increase of 46.66% is expected in the next year compared to the current price of 62.6.

For the next year, analysts expect an EPS growth of 11.48% and a revenue growth 7.24% for 2U3.DE


Analysts
Analysts76
Price Target91.81 (46.66%)
EPS Next Y11.48%
Revenue Next Year7.24%

2U3.DE Financial Highlights

Over the last trailing twelve months 2U3.DE reported a non-GAAP Earnings per Share(EPS) of 2.61. The EPS increased by 0.33% compared to the year before.


Income Statements
Revenue(TTM)10.40B
Net Income(TTM)980.00M
Industry RankSector Rank
PM (TTM) 9.42%
ROA 3.11%
ROE 4.45%
Debt/Equity 0.21
Chartmill High Growth Momentum
EPS Q2Q%8.33%
Sales Q2Q%9.08%
EPS 1Y (TTM)0.33%
Revenue 1Y (TTM)4.94%

2U3.DE Ownership

Ownership
Inst Owners68.23%
Shares499.70M
Float486.45M
Ins Owners0.17%
Short Float %N/A
Short RatioN/A

About 2U3.DE

Company Profile

2U3 logo image Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. The company is headquartered in Fribourg, Fribourg and currently employs 25,942 full-time employees. The company went IPO on 2019-04-09. The firm research, develop, manufacture, distribute and sell a full suite of eye care products within two key businesses: Surgical and Vision Care. The Company’s Surgical business is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end needs of the ophthalmic surgeon. The Company’s Vision Care business comprises of daily disposable, reusable and color-enhancing contact lenses and a portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The firm operates in 60 countries and serves consumers and patients in over 140 countries.

Company Info

IPO: 2019-04-09

ALCON INC

Rue Louis d'Affry 6

Fribourg FRIBOURG CH

Employees: 25942

2U3 Company Website

2U3 Investor Relations

Phone: 41589112222

ALCON INC / 2U3.DE FAQ

What does ALCON INC do?

Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. The company is headquartered in Fribourg, Fribourg and currently employs 25,942 full-time employees. The company went IPO on 2019-04-09. The firm research, develop, manufacture, distribute and sell a full suite of eye care products within two key businesses: Surgical and Vision Care. The Company’s Surgical business is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end needs of the ophthalmic surgeon. The Company’s Vision Care business comprises of daily disposable, reusable and color-enhancing contact lenses and a portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The firm operates in 60 countries and serves consumers and patients in over 140 countries.


What is the current price of 2U3 stock?

The current stock price of 2U3.DE is 62.6 EUR. The price decreased by -0.22% in the last trading session.


Does 2U3 stock pay dividends?

ALCON INC (2U3.DE) has a dividend yield of 0.48%. The yearly dividend amount is currently 0.29.


What is the ChartMill technical and fundamental rating of 2U3 stock?

2U3.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


What is the Price/Earnings (PE) ratio of ALCON INC (2U3.DE)?

The PE ratio for ALCON INC (2U3.DE) is 23.98. This is based on the reported non-GAAP earnings per share of 2.61 and the current share price of 62.6 EUR.


Is ALCON INC (2U3.DE) stock a good buy?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 2U3.DE.